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ABSTRACT
Background and Objectives. Multiple sclerosis (MS) is a chronic inflammatory, autoimmune disease with a still unknown aetio-
logy. The main initial mechanism of demyelination and injury to the central nervous system (CNS) appears to be inflammation. 
Neurotoxicity induced by homocysteine (Hcy) may be a factor affecting this process. 5,10-methylenetetrahydrofolate reductase 
(MTHFR) is an essential enzyme involved in Hcy metabolism. It leads to Hcy remethylation to methionine. In the present study, 
we aimed to investigate a possible association between two variants of MTHFR gene in patients with MS in Poland and healthy 
individuals.
Methods. In this study, we genotyped 174 relapsing-remitting MS patients and 186 healthy controls using the TaqMan 
technique.
Results and Conclusions. It was found that, regardless of the presence of a specific allele, the gender of MS patients affects 
age at the time of the clinical onset of the disease: in rs1801133 for the C allele and T, the average age was 35 years for women 
and 29 for men (p = 0.0004; p = 0.034 respectively). Similarly for the second polymorphism rs1801131 for the A allele and C, the 
average age was 35 years for women and 29 for men (p = 0.001; p = 0.01 respectively). No significant allelic / genotypic frequ-
ency differences have been observed between the studied groups (c.677C > T, CT/TT p = 0.719, p = 0.262; c.1298A > C, AC/CC of 
p = 0.686; p = 0.66). We found no association between polymorphisms of a folate-homocysteine-methionine-SAM metabolising 
gene enzyme and multiple sclerosis in a Polish population.
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(Neurol Neurochir Pol 2019; 53 (3): 194–198)
Introduction
Multiple sclerosis (MS) is a chronic inflammatory, autoim-
mune disease with a still unknown aetiology. The main initial 
mechanism of demyelination and injury to the central nervous 
system (CNS) appears to be inflammation [1]. The neurotoxi-
city induced by homocysteine (Hcy) action is considered to 
be one of the factors that triggers this process. Several studies 
have shown an increase in Hcy levels in patients with MS [2, 3], 
which leads to reactive oxygen species generation as a result 
of sulfhydryl group oxidation. The effect of this process is ex-
cessive N-methyl-D-aspartate receptor stimulation leading to 
neuronal damage through the exaggerated calcium ion influx 
[4, 5]. An important factor necessary for CNS myelination is 
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an appropriate level of S-Adenosylmethionine (SAM). 5,10 –
methylenetetrahydrofolate reductase (MTHFR) is an essential 
enzyme in Hcy metabolism that leads to its remethylation to 
methionine, which is a precursor of SAM. MTHFR is coded by 
a gene localised in one chromosome (gene ID 4524, 1p36.22) 
and is a key folate – homocysteine – methionine – SAM me-
tabolising enzyme [1]. Two common polymorphic variants 
influence MTHFR activity, which can lead to hyperhomo-
cysteinemia. This metabolic effect is considered to be a po-
ssible mechanism predisposing for myelin pathology in MS. 
The C677T and A1289C of MTHFR gene polymorphisms are 
a missense mutation leading to aminoacid change and sub-
sequent reduction in enzyme activity. This has been reported 
as a genetic susceptibility factor in a few population studies 
of relapsing – remitting MS patients [6–8]. The relationship 
between MTHFR polymorphisms and multiple sclerosis has 
not been investigated in a Polish population thus far. In the 
present study, we investigated a possible association between 
two variants of the MTHFR gene in a Polish multiple sclerosis 
population and a control group.  
Materials and Methods
Study population
The study population consisted of 174 unrelated patients 
(124 women and 50 men) with clinically defined relapsing 
– remitting MS according to McDonald’s criteria [9]. All 
patients were recruited from the Department of Neurology, 
Medical University of Bialystok. The average age of the pa-
tients at the time of diagnosis was 40 years (41.14 ± 0.79), 
and the mean disease duration was 8 years (8.12 ± 0.42). 
MS patients were treated with interferon β (a/b), glatiramer 
acetate, natalizumab, or fingolimod. Physical disability was 
assessed using the Expanded Disability Status Scale (EDSS) 
score. The control group included 186 healthy volunteers 
(mean age 38.7 + 1.23; 75 women and 111 men) with no family 
history of any autoimmune disease. The study was approved 
by the local Bioethics Committee (Medical University of 
Bialystok) and written informed consent was obtained from 
all the participants.
MTHFR Genotyping
DNA was extracted from peripheral whole blood leuko-
cytes. Genotyping through a single nucleotide polymorphism 
(SNP) was performed using the 7900HT Fast Real-Time PCR 
System (Applied Biosystems, USA). All SNPs in the MTHFR 
gene (rs1801133 – C677T, rs1801131 – A1298C) were geno-
typed by TaqMan assay, SNP technology, from a ready-to-use 
human probes library (Applied Biosystems, Foster City, CA, 
USA) with the TaqMan Genotyping Master Mix (Applied 
Biosystems, Foster City, CA, USA) in a 20µl reaction volume. 
The final concentration of genomic DNA for all samples in the 
experiment sample was 10ng/µl. The reactions were carried 
out under the following conditions: 10 min at 95°C for starting 
Hot-Start Taq polymerase activity, 40 cycles of 92°C for 15 s 
and 60°C for 1 min.
Statistical analysis
Descriptive statistics including mean, standard error of 
the mean and the median were calculated for selected clini-
cal measurements, henceforth called features. To determine 
whether the features’ distributions statistically significantly 
differed between the defined groups, either the parametric [10] 
or the non-parametric [11] approach was used. The choice of 
appropriate method was made based upon the fulfillment of 
normality and homogeneity of variance assumptions, and the 
non-parametric approach was chosen in the case of violation 
of at least one of the conditions. The normality of the features’ 
distributions was checked using the Shapiro-Wilk test [12] 
and the homogeneity of variances using Levene’s test [13]. To 
address the problem of multiple testing appearing in post-hoc 
analyses, the false discovery rate (FDR) p-value adjustment 
method [14] was applied. Median unbiased estimator (mid-p) 
of the odds ratio, the exact confidence interval and the associa-
ted p-value, both obtained using the mid-p method [15], were 
used to assess the strength of a relationship between genotype 
or allele occurrence and the patient’s status. Significance level 
was set at 0.05 for all calculations. The R software environment 
[16] was exploited for all calculations.
Results
The distribution of alleles and genotypes in the two ana-
lysed groups, MS patients and healthy controls, is shown in 
Table 1. There were no significant differences between the 
presence of the polymorphic variants, allele T and genotypes 
Table 1. Distributions of genotypes and alleles in MTHFR gene poly-
morphisms rs1801133 and rs1801131 in multiple sclerosis and healthy 
groups







CC 94 (54%) 99 (53.2%) NS
CT 67 (38.5%) 80 (43%) NS
TT 13 (7.5%) 7 (3.8%) NS
C 255 (73.3%) 278 (74.7%) NS
T 93 (26.7%) 94 (25.3%) NS
rs 1801131
AA 77 (44.2%) 83 (44.6%) NS
AC 73 (41.9%) 83 (44.6%) NS
CC 24 (13.8%) 20 (10.8%) NS
A 227 (69.6%) 249 (67%) NS
C 121 (30.4%) 123 (33%) NS
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CT/TT of rs1801133 (p = 0.719; p = 0.262), and allele C and 
genotypes AC/CC of rs1801131 (p = 0.686; p = 0.66) in the 
MTHFR gene in both studied groups. We observed a very 
similar count in the MS cases and the controls in allele distri-
bution in both assessed polymorphisms (C - 73.2% vs 74.7%; 
T – 26.7% vs 25.3%; A – 65.2% vs 66.9%; C – 34.7% vs 33%). 
The MS patients and the control group did not significantly 
differ after stratification into sexes (Tab. 2). Nevertheless, 
sex stratification of patients with MS showed statistically 
significant differences in the age of disease onset. Regardless 
of the presence of a specific allele, the sex of patients with 
MS affected the age differences at the time of clinical onset of 
the disease: in rs1801133 polymorphism for the C allele, the 
average age was 35 for women and 29 for men (p = 0.0004); 
for the T allele, the average age was 35 for women and 29 for 
men (p = 0.034). In the rs1801131 polymorphism for the 
A allele, the average age was 35 for women and 29 for men 
(p = 0.001); for the C allele, the average age was 35 for women 
and 29 for men (p = 0.01) (Tab. 3).
There was no statistically significant association between 
MTHFR gene C677T and A1298C polymorphisms and any 
other clinical characteristic features of MS patients (except 
for duration of disease and EDSS scale score).
Discussion
The strong influences of environmental and genetic 
factors are considered in the pathogenesis of MS [17]. In 
many case-control studies in different populations, parti-
cular genes have been found to be possible genetic factors 
that can increase the risk of MS [18–21]. In our study, we 
investigated the possible link between two variants of the 
MTHFR gene in Polish patients with MS and a control group. 
The reduction of the enzyme activity encoded by the MTHFR 
gene, 5.10 methylenetetrahydrofolate reductase, disturbs the 
folate acid metabolism cycle and nucleic acid synthesis, as 
a result of single nucleotide polymorphisms. MTHFR reduces 
5.10 –methylenetetrahydrofolate to 5-methylenetetrahydro-
folate which is a key factor of remethylation of neurotoxic 
homocysteine to methionine. The inhibition of this process 
leads to hyperhomocysteinemia and causes the formation of 
free radicals damaging the myelin. Methionine is a precursor 
of S-Adenosylmethionine, which is essential for CNS myeli-
nation [1, 5].
We assessed the two molecular variants of the MTHFR 
gene, c.677C > T and c.1298A > C, which lead to decreased 
product activity encoded by this gene. To the best of our kno-
wledge, this is the first study based on a Polish population. In 
both analysed polymorphisms, regardless of the presence of 
the wild type or polymorphic allele, the average age at diag-
nosis with MS in women was higher than in men (35 years 
Table 3. Mean age in years at disease onset of MS and distributions of 
alleles in MTHFR gene polymorphisms rs1801133 and rs1801131 in female 
and male patients
SNP Female MS Male MS P 
(95% CI)
rs1801133
C 34.6 (± 0.80) 29.13 (± 0.94) 0.0004
T 34.57 (± 1.37) 29.3 (± 1.59) 0.034
rs1801131
A 34.13 (± 0.86) 29.47 (± 0.99) 0.001
C 34.13 (± 1.15) 28.53 (± 1.41) 0.01
Table 2. Distributions of genotypes and alleles in MTHFR gene polymorphisms rs1801133 and rs1801131 in multiple sclerosis and healthy groups with sex 
stratification










CC 69 (55.6%) 24 (48%) 41 (54.6%) 58 (52.3%) NS
CT 43 (34.7%) 22 (44%) 34 (45.4%) 46 (41.4%) NS
TT 9 (7.3%) 4 (8%) - 7 (6.3%) NS
C 181 (73%) 70 (70%) 116 (77.3%) 162 (73%) NS
T 61 (27%) 30 (30%) 34 (22.7%) 60 (27%) NS
rs 1801131
AA 56 (45.2%) 23 (46%) 38 (50.6%) 45 (40.5%) NS
AC 48 (38.7%) 23 (46%) 29 (38.7%) 54 (48.6%) NS
CC 20 (16.1%) 4 (8%) 8 (10.7%) 12 (10.9%) NS
A 154 (63.6%) 69 (69%) 105 (70%) 144 (65%) NS
C 88 (36.4%) 31 (31%) 45 (30%) 78 (34%) NS
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vs 29 years). This means that sex is a modulating factor that 
can influence the age of multiple sclerosis onset. This result 
is consistent with data published by Confavreux and Vukusic 
from a French population [22]. However, there is some evi-
dence that women have earlier onset of MS than men [23]. 
These differences may be related to the existence of various 
demographic, geographic, genetic, or environmental factors 
that affect the age of MS onset in both women and men.
The results of the presented study did not show an as-
sociation between the studied polymorphisms and multiple 
sclerosis in our population. There were no significant diffe-
rences between the distribution of missense variants in the 
MTHFR gene in both studied groups. We also analysed the 
association of SNPs between the chosen clinical features of 
patients with MS, but they did not bring the expected effect. 
Our results are comparable with some earlier published 
studies in other populations. Szvetko et al. did not find any 
link between the c.1298A > C variant of the MTHFR gene 
in an Australian multiple sclerosis population. The analysed 
group of patients had lower results than in our investigation 
[15]. In a Tunisian population, Mrissa et al. obtained similar 
results as in the present study in relation to variant C677T, but 
opposite results in terms of variant A1298C. They observed 
an association of the c.1298A > C missense variant with the 
studied MS population [7]. In another case-control study in 
Turkish MS patients, the authors demonstrated statistically 
significant differences between the analysed groups. These 
associations were observed when patients were compared 
with the controls according to CC genotype versus CT + TT 
genotypes [8].  Klotz et al. published very interesting data. 
They found the occurrence of the wild type of a homozygo-
sity AA variant in a group of healthy controls with a higher 
frequency than in patients with MS. This may suggest that 
the presence of this genotype is a protective factor against 
MS development. In addition, the authors did not show a re-
lationship of variant C677T with the MS group [6]. Among 
the studies described above, none of them revealed a rela-
tionship with the age of disease onset or sex stratification of 
the studied polymorphisms.
The discrepancies between the data of other studies and 
our results may be due to various reasons, with the most no-
table being inter-ethnic and geographical genetic differences. 
These discrepancies may also depend on allele frequency, 
genome location on chromosomes, various LD patterns (lin-
kage disequilibrium) in the populations, different evolutionary 
histories of genes affecting complex diseases, and the effect of 
numerous environmental factors. Our results could also have 
been affected by the small study groups, which may explain the 
lack of statistical significance. Moreover, the overall statistical 
approach could be impacted by the research design and criteria 
for patient inclusion. Replication in a larger sample set, and 
other populations, is necessary to confirm these findings and 
to expand our knowledge in this area.
Clinical implications
The results of our research are contradictory to those 
of some reports, but they also confirm others. The recently 
published results of a meta-analysis clearly indicate a lack 
of a relationship between both polymorphic variants c.677C 
> T and c.1298A > C of MTHFR gene with MS. The analysed 
population consisted of approximately 2,500 patients with MS 
and almost 3,000 healthy individuals [25].
Our results encourage us to do further research. We found 
that, regardless of the presence of a specific allele, the sex of 
MS patients affects the age differences at the time of the cli-
nical onset of the disease. We plan to expand the study group 
in the future and include patients with other types of MS 
(i.e. primary progressive and secondary progressive).
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